Veristat

It’s almost time! Join Veristat, ADC Therapeutics, Supply Chain Operations, and PrimeTax at the Product Launch Readiness event on October 24 in Lausanne. Discover valuable insights on how Zynlonta™ was successfully launched in Europe and how cross-functional teamwork, careful planning, and the right partners made it all possible. Whether you’re in clinical development or preparing for your next big launch, this is your chance to gain practical insights from industry experts. There are still a few spots left – register now! https://lnkd.in/gBtDQm3Y #LifeSciences #ProductLaunchSuccess #VeristatEvents

Throwback Thursday: Reflecting on Our Growth 🚀 In 2016, we made a significant leap in expanding our global footprint by acquiring Spero Oncology and launching our Strategic Consulting Group. This growth has strengthened our oncology expertise and consulting services, enabling us to help clients navigate complex clinical trials more effectively and drive greater innovation in the fight against cancer. 📈 Discover how our Strategic Consulting service can support your trial's success today: https://lnkd.in/d6zFNfB7 #ThrowbackThursday #VeristatMilestones #ClinicalResearch #CRO #OncologyExcellence

💉 As flu season arrives, vaccines play a crucial role in protecting public health—especially when developed through rigorous clinical trials. 🧪 But vaccines go beyond just the flu. At Veristat, we’ve supported the development of life-saving vaccines, from infectious diseases like COVID-19 to cancer vaccines. With over 175+ vaccine trials and consulting projects, our expertise helps bring vaccines to market safely and quickly. Whether it’s navigating regulatory challenges or ensuring rapid patient recruitment, we’re here to ensure vaccines reach those who need them most. Want to know more about our role in vaccine development? Let’s talk 👉 https://hubs.li/Q02S3kwR0 #FluSeason #Vaccines #ClinicalTrials #PublicHealth #Veristat

Don't miss our plenary presentation at the World Orphan Drug Congress Europe in Barcelona👇💡    Unique Challenges in Recruiting Patients for Rare Indication Pediatric Studies: Overcoming Difficulties through a Site and CRO Perspective    📆 October 24, 2024  🕛12:10 pm CET   Meet scientific experts Rachel Paiva Petean Abu Taleb, Medical Monitor, Veristat, together with Joana Claverol, Clinical Research Director, at Sant Joan de Déu Research Foundation. This session will delve into the complexities of patient recruitment in rare pediatric populations from both a CRO perspective as well as a world leading pediatric clinical site.    👋 See you in Barcelona! https://lnkd.in/gmJv4Zbu   #Veristat #PatientRecruitment #WODC2024 #RareDiseases

The IMDRF released an overview of the implementation status of all International Medical Device Regulators Forum (IMDRF) technical documents up until 30 August 2024. The document reflects IMDRF's mission of strategically accelerating international medical device regulatory convergence to promote an efficient and effective regulatory model for medical devices. 🔭 💡 The overview is organized by levels of implementation and by medical device regulators. Download the final document: https://hubs.li/Q02S3MKR0

When treating diseases in children—especially rare or ultra-rare conditions with limited patient populations and no alternative treatments—getting it right from the start is vital. At Veristat, we’re committed to advancing pediatric health by offering: 🧠 Strategic advice from our scientific experts to plan successful pediatric clinical development programs 🏥 Operational support to find and treat the right patients, ensuring your clinical trial moves forward to its next milestone This National Child Health Day, we reaffirm our dedication to supporting pediatric trials and making a difference in the lives of children facing rare diseases. Learn more: https://hubs.li/Q02S3hrH0 #ChildHealthDay #PediatricResearch #RareDiseases #ClinicalTrials #Veristat

The European Medicines Agency agency issued a set of guiding principles and recommendations for the use of large language models (LLMs) by regulatory agencies in the context of the EU’s artificial intelligence (AI) workplan. Recommendations include: 👉 Ensuring the safe input of data 👉 Applying critical thinking and cross-checking outputs 👉 Keeping up to date with how to make best use of LLMs 👉 Knowing who to consult and report incidents to 🔎 Recommendations https://hubs.li/Q02S3k640 🔎 Guiding principles https://hubs.li/Q02S3jrg0

Are you involved in bioresearch monitoring? FDA published a final guide on technical specifications for bioresearch monitoring, providing general considerations on: ➡ Clinical study-level information ➡ Subject-level data line listings by clinical site ➡ Summary-level clinical site dataset ➡ Submitting BIMO clinical data in the ECTD format Required data sets are used by the Center for Drug Evaluation and Research (CDER) to plan Bioresearch Monitoring (BIMO) inspections, among other submissions. Download the document: https://hubs.li/Q02SbYfj0

The landscape of clinical trials is evolving, with decentralized and hybrid models now at the forefront. At Veristat, we're dedicated to advancing patient-centricity by delivering flexible clinical trial solutions directly to patients' homes. Our approach integrates remote monitoring with traditional on-site visits, offering a customizable experience tailored to the needs of each patient and trial. From at-home dosing and lab work to on-site visits when necessary, we ensure that trials are both accessible and effective. This not only improves patient engagement but also enhances the diversity and quality of data collected. As the industry continues to embrace these innovative trial designs, Veristat is committed to leading the way, making clinical research more adaptable, inclusive, and patient-focused. #DecentralizedTrials #HybridTrials #PatientCentricity #ClinicalResearch #Veristat #InnovationInHealthcare #FutureOfMedicine * https://lnkd.in/ewEShctB

European Commission published the report on the future of European competitiveness, highlighting several proposals to increase the competitiveness of the EU pharmaceutical sector, including: ✔ Investing at least EUR 800 billion extra to meet key competitiveness objectives per year across industries ✔ Substantially increasing public R&D investments in pharmaceutical research ✔ Maximizing the impact of the Health Data Space ✔ Streamlining the set-up and management of multi-country trials ✔ Expediting market access through coordinated stakeholders’ actions ✔ Providing clear and timely guidance on the use of artificial intelligence (AI) in the lifecycle of medicines The report contains useful insights on how the European Union intends to stay competitive and prosperous. Download here: https://hubs.li/Q02S1b490